Literature DB >> 8206406

Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer.

F Guidozzi1, J H Ball.   

Abstract

This retrospective descriptive study provides our experience with a subset of 30 patients with Stage III or Stage IV ovarian cancer who presented at initial laparotomy with advanced disease in whom large (greater than 10 cm) confluent nodules, plaques, or nodal metastatic deposits were found intraperitoneally. The nature of the extirpative procedures performed resulted in extensive primary cytoreductive surgery involving multiple organ resection. All the patients had removal of their primary tumor from the pelvis, an omentectomy, and appendectomy. In addition to resection of rectosigmoid colon in 27 patients, 11 had concomitant resection of the small bowel and 13 of the large bowel, 3 of which were hemicolectomy. In the remaining 3 patients who did not have rectosigmoid resection a hemicolectomy was performed, 2 of which also had resection of small bowel. Three patients required a primary colostomy, while 1 had a colostomy as a secondary procedure following the development of a rectovaginal fistula. Eight patients had a splenectomy, 2 had resection of portion of the tail of the pancreas, 10 had a partial urinary bladder cystectomy and 2 had a nephrectomy. The average operating time and blood loss was 5 hr 18 min and 2900 ml, respectively. Two patients died within 48 hr postoperatively, two required a second laparotomy for persistent intraabdominal bleeding, and six developed late thrombotic complications. In total 43% of the patients developed serious postoperative complications. We present our findings and allude to the morbidity and mortality that may ensue when such extensive cytoreductive surgery is undertaken.

Entities:  

Mesh:

Year:  1994        PMID: 8206406     DOI: 10.1006/gyno.1994.1142

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Splenectomy and distal pancreatectomy in advanced ovarian cancer.

Authors:  Eun Ji Lee; Soo Jin Park; Hee Seung Kim
Journal:  Gland Surg       Date:  2021-03

2.  Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008.

Authors:  Jenny J Lin; Natalia Egorova; Rebeca Franco; Monica Prasad-Hayes; Nina A Bickell
Journal:  Obstet Gynecol       Date:  2016-01       Impact factor: 7.661

3.  Complications and Outcomes of Diaphragm Surgeries in Epithelial Ovarian Malignancies.

Authors:  Amrita Datta; Ajit Sebastian; Rachel George Chandy; Vinotha Thomas; Dhanya Susan Thomas; Reka Karuppusami; Anitha Thomas; Abraham Peedicayil
Journal:  Indian J Surg Oncol       Date:  2021-09-08

4.  Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT).

Authors:  Fabian Trillsch; Jan David Ruetzel; Uwe Herwig; Ulrike Doerste; Linn Woelber; Donata Grimm; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  J Ovarian Res       Date:  2013-07-09       Impact factor: 4.234

5.  Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.

Authors:  Upasana Baruah; Debabrata Barmon; Amal Chandra Kataki; Pankaj Deka; Munlima Hazarika; Bhargab J Saikia
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

6.  Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.

Authors:  C William Helm; J Christopher States
Journal:  J Ovarian Res       Date:  2009-01-14       Impact factor: 4.234

7.  Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.

Authors:  Gilles Houvenaeghel; Alexandre de Nonneville; Guillaume Blache; Max Buttarelli; Camille Jauffret; Djamel Mokart; Laura Sabiani
Journal:  J Gynecol Oncol       Date:  2022-02-04       Impact factor: 4.756

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.